Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

and we are excited to be moving our clinical program forward. We are very pleased that the MMRC sponsorship has made the rapid initiation of our Phase 2 trials possible and has enabled us to reach out to a larger group of myeloma patients. The thoughtful scientific expertise and collaborative effort of this group have helped speed development of new agents in the field of multiple myeloma," said Lori A. Kunkel, M.D., Chief Medical Officer of Proteolix, Inc.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 Member Institutions: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, Saint Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University. In addition to these trials with Proteolix, the MMRC is supporting six other clinical trials exploring several investigative agents.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas- genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy ... clinics opened in Memphis and ... added in Springfield on September 24 and ... to open October 22.  MinuteClinic is the largest and fastest growing ... . The Memphis -area clinics ...
(Date:9/19/2014)... 19, 2014 According to ... (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, ... & Rotary) & Geography - Global Trends & ... segments the lyophilization market on the basis of ... projections of the market size of each of ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Pressure ... today announced it has received and approved all ... HT48 instruments and has begun to manufacture the ... first instrument will be ready for shipment by ... built and released at a rate of about ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 The ... important partnership with the National Fire Protection Association ... The collaboration, formalized today in a Memorandum of ... Members, factories, workers and other stakeholders with information, ... help protect the health and safety of workers ...
(Date:9/19/2014)... to treat and cure disease is a hugely ... by the inability of doctors and scientists to effectively ... in patients without resorting to invasive procedures, like tissue ... the online journal Magnetic Resonance in Medicine , ... of Medicine, University of Pittsburgh and elsewhere describe the ...
(Date:9/19/2014)... 2014) - New research published today in the online ... could reach 6,800 in West Africa by the end ... enacted. , Arizona State University and Harvard University ... of rise in cases significantly increased in August in ... quarantine was put in place, indicating that the mass ...
(Date:9/19/2014)... Researchers at Jacksonville,s campus of Mayo Clinic have ... say contributes to both overproduction of toxic protein in ... well as loss of communication between neurons both ... study, in the online issue of Neuron ... defect with drugs "may rejuvenate or rescue this pathway," ...
Breaking Medicine News(10 mins):Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A better way to track emerging cell therapies using MRIs 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2
... Self-Funding,Healthcare Conference and Expo will provide employers and health ... both carriers and,brokers during a June 1-3, 2009 conference ... The conference is unique, as it is designed and ... Karrie Andes, Director of Human,Resources for Deffenbaugh Industries, ...
... (Nasdaq: DYNT ) today announced that a ... the SEC, gives the company until approximately June 28, ... bid rule."We are pleased that NASDAQ has further extended ... market environment," stated Kelvyn H. Cullimore Jr., chairman and ...
... tumors seen in mouse study , , MONDAY, Dec. 29 ... phosphates found in many natural and processed foods accelerated ... researchers report. , "Our study suggests that dietary regulation ... treatment as well as prevention," Myung-Haing Cho, lead author ...
... widespread media attention given to studies that have indicated ... new study shows just one-third of children who are ... pediatrician. The study, led by researchers at The ... Medicine in Cleveland, also stresses that this failure to ...
... Technology,Inc. ("Versus" or the "Company") announced revenues of ... compared to revenues of $5,566,000 for fiscal,year 2007. ... 31, 2008, were,$1,748,000 compared to revenues of $2,012,000 ... can vary significantly depending on the timing and,delivery ...
... MANHATTAN, KSThe Centers for Disease Control and Prevention and ... 30 minutes of moderate-intensity physical activity on most days ... optimal health. This recommendation is especially important for older ... requirement, yet are more at risk for chronic diseases ...
Cached Medicine News:Health News:Spending Too Much on Healthcare? This Employer-Designed Conference Will Inspire! 2Health News:NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance 2Health News:Food Phosphates Might Spur Lung Cancer 2Health News:Food Phosphates Might Spur Lung Cancer 3Health News:Can't chalk it up to 'baby fat' 2Health News:Versus Technology Announces Fiscal Year Results 2Health News:Versus Technology Announces Fiscal Year Results 3Health News:Versus Technology Announces Fiscal Year Results 4Health News:Versus Technology Announces Fiscal Year Results 5Health News:Versus Technology Announces Fiscal Year Results 6Health News:Versus Technology Announces Fiscal Year Results 7Health News:Another reason to get your hands dirty 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: